solute carrier family 38 member 6Genealiases: NAT-1 · SNAT6
Q-omics provides the consensus-scored SLC38A6 profile across patient tissues and cancer cell-line models. SLC38A6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC38A6 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SLC38A6 RNA expression shows 18,754 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where SLC38A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC38A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC38A6 survival associations across molecular data types. SLC38A6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC38A6 RNA expression–survival associations across cancer types. High SLC38A6 expression shows unfavorable associations in UVM, LIHC, LGG, KICH and SCLC, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC38A6 RNA expression.
This table summarizes SLC38A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC38A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC38A6 shows higher tumor expression in HNSC, BLCA, KIRC, LIHC, KIRP and STAD. The HNSC box plot shows higher SLC38A6 RNA expression in tumor versus normal tissue (log2 FC = +0.827, t-test p < 0.001).
This table shows molecular features associated with SLC38A6 in patient tissues and cancer cell lines. In patient samples, SLC38A6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC38A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
